Clinical Trials Directory

Trials / Sponsors / Cerevel Therapeutics, LLC

Cerevel Therapeutics, LLC

Industry · 22 registered clinical trials.

StatusTrialPhaseStarted
CompletedA Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Or
Healthy Participants
Phase 12024-05-29
CompletedA Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Partici
Healthy Participants
Phase 12024-05-10
CompletedA Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Ma
Healthy Participants
Phase 12024-03-04
CompletedA Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and o
Healthy Volunteers
Phase 12023-08-15
CompletedA Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets
Healthy Participants
Phase 12023-07-19
CompletedThe Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult Participants
Healthy
Phase 12023-06-08
CompletedOpen-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participa
Healthy Participants
Phase 12023-04-17
CompletedPositron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Recept
Opioid Use Disorder
Phase 12023-03-02
CompletedMultiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Pa
Parkinson Disease
Phase 12022-12-15
CompletedStudy to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics
Parkinson Disease
Phase 12022-10-19
CompletedTo Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compare
Renal Impairment
Phase 12022-05-10
CompletedTo Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic I
Hepatic Impairment
Phase 12022-04-29
CompletedTrial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia
Blood Pressure, Schizophrenia
Phase 12022-01-24
CompletedPharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulatio
Schizophrenia
Phase 12021-12-29
CompletedRelative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Health
Healthy
Phase 12021-11-02
CompletedA Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants
Healthy Participants
Phase 12021-10-18
CompletedPET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing
Schizophrenia
Phase 12021-06-01
CompletedA Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects
Panic Disorder
Phase 12020-10-06
CompletedAn Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects
Healthy Subjects
Phase 12020-02-04
CompletedA 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease
Parkinson Disease
Phase 12020-01-08
TerminatedA Single Ascending Dose Trial of CVL-936 in Healthy Subjects
Substance Use Disorders (SUD)
Phase 12019-12-16
CompletedA Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia
Schizophrenia
Phase 12019-10-15